Raoudha Soufi‐Mahjoubi

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Charles S. Fuchs, John L. Marshall, Edith P. Mitchell et al. · Journal of Clinical Oncology · 2007 · 857 citations

Medicine, Oncology, Pharmacology +17

Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer

Nadine Jackson, José Barrueco, Raoudha Soufi‐Mahjoubi et al. · Cancer · 2009 · 61 citations

Medicine, Oncology, Pharmacology +16

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: Updated efficacy data

Charles S. Fuchs, John L. Marshall, E. Mitchell et al. · Journal of Clinical Oncology · 2007 · 29 citations

Medicine, Oncology, Pharmacology +7

Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those ≤65: The BICC-C study

José Barrueco, J. Marshall, E. Mitchell et al. · Journal of Clinical Oncology · 2007 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +10